This article's lead is ready for translation. Click for more information.

Budesonide/salmeterol

From WikiProjectMed
Jump to navigation Jump to search
Budesonide/salmeterol
Combination of
BudesonideInhaled corticosteroid (ICS)
SalmeterolLong-acting beta agonist (LABA)
Names
Trade namesLabazenit
Other namesBudesonide/salmeterol xinafoate
Clinical data
Main usesAsthma[1]
Side effectsThroat inflammation, headache, voice changes, worsened asthma[1]
Routes of
use		Inhaled[1]

Budesonide/salmeterol (B/S), sold under the brand name Labazenit, is a combination medication used in the long-term treatment of asthma.[1] It main be used when an inhaled steroid alone is insufficient.[1] It is used by breathing the medication into the lungs.[1]

Side effects may include throat inflammation, headache, voice changes, and worsened asthma.[1] Serious side effects are uncommon.[1] It contains budesonide, an inhaled corticosteroid (ICS) and salmeterol, a long-acting beta agonist (LABA).[1]

It was denied approval in Europe in 2013.[2] It had not been approved for medical use in any country as of 2015.[1] It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide/formoterol.[3]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Popov, TA; De Niet, S; Vanderbist, F (February 2016). "Budesonide/salmeterol in fixed-dose combination for the treatment of asthma". Expert review of respiratory medicine. 10 (2): 113–25. doi:10.1586/17476348.2016.1133302. PMID 26677916.
  2. ↑ "Labazenit". European Medicines Agency. 17 September 2018. Archived from the original on 3 June 2023. Retrieved 23 August 2023.
  3. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

Retrieved from "https://mdwiki.org/w/index.php?title=Budesonide/salmeterol&oldid=1458895"